Quick Answer
Barinthus Biotherapeutics plc. reported R&D Expense of $25.56 million for fiscal year 2025.
Barinthus Biotherapeutics plc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $25.56M | -39.5% |
| 2024 | $42.24M | -5.9% |
| 2023 | $44.87M | +6.0% |
| 2022 | $42.35M | +107.9% |
| 2021 | $20.37M | +41.6% |
| 2020 | $14.39M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.39M | -51.6% | -32.2% |
| June 30, 2025 | $7.95M | -31.8% | -4.1% |
| March 31, 2025 | $8.29M | -25.5% | -25.6% |
| September 30, 2024 | $11.14M | -26.4% | -4.5% |
| June 30, 2024 | $11.66M | -13.9% | +4.8% |
| March 31, 2024 | $11.12M | +13.4% | -26.5% |
| September 30, 2023 | $15.14M | +55.4% | +11.8% |
| June 30, 2023 | $13.54M | +39.3% | +38.0% |
- Barinthus Biotherapeutics plc. showed a decrease of -39.5% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Barinthus Biotherapeutics plc.’s r&d expense has grown by 77.7% (from $14.39 million to $25.56 million).
- The most recent figure is from Barinthus Biotherapeutics plc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: